MolecularAI / REINVENT4
AI molecular design tool for de novo design, scaffold hopping, R-group replacement, linker design and molecule optimization.
Why this job: works in the areas we cover, but does not say which job it does
What it does
REINVENT is a molecular design tool for de novo design, scaffold hopping, R-group replacement, linker design, molecule optimization, and other small molecule design tasks. REINVENT uses a Reinforcement Learning (RL) algorithm to generate optimized molecules compliant with a user defined property profile defined as a multi-component score. Transfer Learning (TL) can be used to create or pre-train a model that generates molecules closer to a set of input molecules.
Get started
No single install command. Read the steps in the README (opens in new tab)
- Maintenance
- Active
- Last commit 6 days ago
- Stars
- 904
- +8 this week
- Licence
- Apache-2.0
- Allows business use
- Downloads for
- None listed
- No release files
- Latest version
- v4.9
- Released 6 days ago
- Built with
- Python
- 99% of the code
Is it looked after?
- Contributors
- Not stated
- Last 90 days
- Issues
- 99% closed
- 1 still open
- Pull requests
- 56 merged
- 0 waiting
- Releases
- 10
- 3 in the last year
- Contributing guide (opens in new tab)
- No security policy
- No code of conduct
Similar repos
| Repo | Stars | Last commit | Licence | Downloads for |
|---|---|---|---|---|
| Dunni3 / FlowMol | 224 | 6 months ago | MIT | No downloads |
| MLCIL / scikit-fingerprints | 404 | 17 days ago | MIT | No downloads |
| HUBioDataLab / DrugGEN | 107 | 3 months ago | GPL-3.0 | No downloads |
More: languages, topics and project record
Languages
- Python 99%
- Shell 1%
- CSS <1%
Topics
- ai
- astrazeneca
- cheminformatics
- chemistry
- deep-learning
- denovo-design
- drug-design
- drug-discovery
- generative-ai
- ml
- molecule-generation
- neural-networks
Project record
- JobOther AI tools
- StatusListed
- Commits371
- Forks242
- Watching25
- Stars in 28 days+26
- CreatedOct 20, 2023
- First seen by usNov 7, 2026
- CheckedNov 8, 2026
